Spinogenix Announces Open Enrollment for Phase 2 Study Evaluating SPG302 for the Treatment of Alzheimer’s Disease
Press Release Spinogenix Announces Open Enrollment for Phase 2 Study Evaluating SPG302 for the Treatment of Alzheimer’s Disease SPG302 is a once-a-day pill with the potential to regenerate synapses to reverse declines in cognitive function in people with Alzheimer’s disease LOS ANGELES, Calif., August 1, 2024 — Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class […]
Spinogenix Announces Enrollment is Open for its Phase 2 Clinical Trial of SPG601 Fragile X Syndrome
Press Release Spinogenix Announces Enrollment is Open for its Phase 2 Clinical Trial of SPG601 in Fragile X Syndrome U.S. FDA has granted Orphan Drug Designation to SPG601 for the Treatment of Fragile X SPG601 is a novel small molecule that works by correcting specific synaptic dysfunctions in the brain to address core symptoms of Fragile […]
Spinogenix Announces Approval from the Australia Human Research Ethics Committee to Initiate a Phase 2 Human Clinical Trial of SPG302 for the Treatment of Alzheimer’s Disease
Press Release Spinogenix Announces Approval from the Australia Human Research Ethics Committee to Initiate a Phase 2 Human Clinical Trial of SPG302 for the Treatment of Alzheimer’s Disease Phase 2 study is designed to evaluate the safety, tolerability, and pharmacodynamics of SPG302 in adult participants with mild-to-moderate Alzheimer’s disease. SPG302 is also being evaluated in […]
Spinogenix Announces FDA Clearance of IND Application for SPG302, a Novel Therapy for the Treatment of ALS
Press Release Spinogenix Announces FDA Clearance of IND Application for SPG302, a Novel Therapy for the Treatment of ALS SPG302 is being developed as a once-a-day pill with the potential to regenerate synapses to reverse declines in cognitive and motor function in people with ALS LOS ANGELES, Calif., May 29, 2024 — Spinogenix, Inc., a […]
Spinogenix Announces U.S. FDA Orphan Drug Designation Granted to SPG601 for the Treatment of Fragile X Syndrome
Press Release Spinogenix Announces U.S. FDA Orphan Drug Designation Granted to SPG601 for the Treatment of Fragile X Syndrome Receiving Orphan Drug Designation for SPG601 emphasizes the pressing demand for novel therapies for individuals living with Fragile X Syndrome LOS ANGELES, Calif., May 20, 2024 — Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering first-in-class therapeutics […]
Spinogenix Announces U.S. FDA Approval of its Investigational New DrugApplication for its Phase 2a Clinical Trial of SPG601 for Fragile X Syndrome
Press Release Spinogenix Announces U.S. FDA Approval of its Investigational New Drug Application for its Phase 2a Clinical Trial of SPG601 for Fragile X Syndrome SPG601 is a once-a-day pill that works by restoring synaptic function to address core symptoms of Fragile X Syndrome LOS ANGELES, Calif., April 15, 2024 — Spinogenix, Inc., a clinical-stage […]
Spinogenix Announces Second Grant Award from U.S. Department of Defense to Further Advance SPG302, the First Synaptic Regenerative Drug to Treat Amyotrophic Lateral Sclerosis (ALS)
Press Release Spinogenix Announces Second Grant Award from U.S. Department of Defense to Further Advance SPG302, the First Synaptic Regenerative Drug to Treat Amyotrophic Lateral Sclerosis (ALS) LOS ANGELES, Calif., Sept. 26, 2023 — Spinogenix, Inc., a clinical-stage biopharmaceutical company developing novel small molecule drugs for neurodegenerative conditions, today announced that it has been awarded […]
Spinogenix Awarded $3 Million NIH Grant to Support Continued Development of SPG302, the First Synaptic Regenerative Therapeutic for Alzheimer’s Disease
Press Release Spinogenix Awarded $3 Million NIH Grant to Support Continued Development of SPG302, the First Synaptic Regenerative Therapeutic for Alzheimer’s Disease Treatment Could Help Restore Brain Functions Lost in Many Neurodegenerative Disorders LOS ANGELES, Calif., (September 12, 2023) – Spinogenix, Inc., a clinical-stage biopharmaceutical company developing novel small molecule drugs for neurological conditions, today […]
Spinogenix Receives Approval from the Australia Human Research Ethics Committee to Initiate a Phase 1 Human Clinical Trial of SPG302, a Novel Regenerative Drug for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
Press Release Spinogenix Receives Approval from the Australia Human Research Ethics Committee to Initiate a Phase 1 Human Clinical Trial of SPG302, a Novel Regenerative Drug for the Treatment of Amyotrophic Lateral Sclerosis (ALS) Treatment Could Help Restore Brain Functions Lost in Many Neurodegenerative Disorders LOS ANGELES, Calif., July 10, 2023 (GLOBE NEWSWIRE) — Spinogenix, […]
Spinogenix Granted FDA Orphan Drug Designation for SPG302 for the Treatment of Amyotrophic Lateral Sclerosis
Press Release Spinogenix Granted FDA Orphan Drug Designation for SPG302 for the Treatment of Amyotrophic Lateral Sclerosis Treatment Could Help Restore Brain Functions Lost in Many Neurodegenerative Disorders LOS ANGELES, Calif., June 07, 2021 (GLOBE NEWSWIRE) — Spinogenix, Inc. a pharmaceutical company focused on the development of novel synaptogenic small molecule therapies for central nervous […]
